Mankind Pharma Income Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Revenue	139,141	122,074	102,604	87,494	77,816	62,144
Revenue Growth (YoY)	19.53%	18.98%	17.27%	12.44%	25.22%	5.83%
Cost of Revenue	41,397	36,596	33,056	30,031	24,879	18,471
Gross Profit	97,744	85,479	69,549	57,463	52,937	43,673
Selling, General & Admin	39,291	34,734	28,830	23,126	20,934	18,195
Other Operating Expenses	24,642	20,461	15,432	15,195	12,014	8,386
Operating Expenses	72,873	61,408	48,047	41,580	34,614	27,770
Operating Income	24,871	24,071	21,502	15,883	18,322	15,903
Interest Expense	-6,796	-4,209	-278.2	-402.74	-557.8	-193.03
Interest & Investment Income	679.1	679.1	396.1	127.67	129.25	387.27
Earnings From Equity Investments	110.2	122.4	152.1	124.24	144.48	116.77
Currency Exchange Gain (Loss)	195.5	195.5	84.4	104.06	88.45	5.02
Other Non Operating Income (Expenses)	705.1	1,115	878.6	536.42	486	51.17
EBT Excluding Unusual Items	19,766	21,974	22,735	16,372	18,613	16,270
Impairment of Goodwill	-	-	-	-38.52	-	-
Gain (Loss) on Sale of Investments	1,608	1,608	1,295	374.31	1,129	628.65
Gain (Loss) on Sale of Assets	1,614	1,614	4.8	16.65	-37.41	-30.45
Asset Writedown	-50.2	-50.2	-91.6	-97.08	-57.63	-38.88
Other Unusual Items	-1,058	8.1	24.8	41.53	85.27	77.21
Pretax Income	21,889	25,163	23,979	16,712	19,746	16,916
Income Tax Expense	3,813	5,097	4,572	3,616	5,216	3,986
Earnings From Continuing Operations	18,077	20,066	19,408	13,097	14,530	12,930
Earnings From Discontinued Operations	-43.4	45.3	9.8	-	-	-
Net Income to Company	18,033	20,111	19,418	13,097	14,530	12,930
Minority Interest in Earnings	-239.8	-201.6	-288.7	-278.17	-194.81	-276.07
Net Income	17,794	19,910	19,129	12,819	14,335	12,654
Net Income to Common	17,794	19,910	19,129	12,819	14,335	12,654
Net Income Growth	-12.84%	4.08%	49.23%	-10.58%	13.28%	22.81%
Shares Outstanding (Basic)	412	404	401	401	401	401
Shares Outstanding (Diluted)	413	405	401	401	401	401
Shares Change (YoY)	2.76%	0.88%	0.14%	0.00%	-	-
EPS (Basic)	43.15	49.28	47.75	32.00	35.78	31.59
EPS (Diluted)	43.10	49.19	47.68	32.00	35.78	31.59
EPS Growth	-15.18%	3.16%	49.02%	-10.57%	13.27%	22.82%
Free Cash Flow	-	19,526	18,371	10,243	4,549	8,318
Free Cash Flow Per Share	-	48.25	45.79	25.57	11.36	20.77
Gross Margin	70.25%	70.02%	67.78%	65.68%	68.03%	70.28%
Operating Margin	17.88%	19.72%	20.96%	18.15%	23.55%	25.59%
Profit Margin	12.79%	16.31%	18.64%	14.65%	18.42%	20.36%
Free Cash Flow Margin	-	16.00%	17.90%	11.71%	5.85%	13.38%
EBITDA	32,331	29,898	25,152	19,051	19,910	17,038
EBITDA Margin	23.24%	24.49%	24.51%	21.77%	25.59%	27.42%
D&A For EBITDA	7,459	5,827	3,649	3,168	1,588	1,135
EBIT	24,871	24,071	21,502	15,883	18,322	15,903
EBIT Margin	17.88%	19.72%	20.96%	18.15%	23.55%	25.59%
Effective Tax Rate	17.42%	20.26%	19.06%	21.63%	26.42%	23.56%
Revenue as Reported	144,099	127,442	105,407	88,780	79,776	63,854
Advertising Expenses	-	7,554	6,008	3,737	4,516	3,857

Source: S&P Global Market Intelligence. Standard template. Financial Sources.